A multicenter, double-blind, randomized, placebo-controlled dose-ranging finding study of once-daily dosing of Sitaglipin (MK-0431) in patients with type 2 diabetes mellitus who have inadequate glycaemic control

Trial Profile

A multicenter, double-blind, randomized, placebo-controlled dose-ranging finding study of once-daily dosing of Sitaglipin (MK-0431) in patients with type 2 diabetes mellitus who have inadequate glycaemic control

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Feb 2014 Results published in the Drugs and Aging.
    • 30 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top